Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Inspyr TherapeuticsVIVUSAnthera PharmaceuticalsFutureWorldCapstone Therapeutics
SymbolOTCMKTS:NSPXOTCMKTS:VVUSQOTCMKTS:ANTHOTCMKTS:FWDGOTCMKTS:CAPS
Price Information
Current Price$0.01$0.12$0.07$0.00$36.01
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score0.50.60.50.50.8
Analysis Score0.00.00.00.00.0
Community Score2.42.52.52.33.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.8
Earnings & Valuation Score0.00.60.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market Cap$5.40 million$2.10 million$942,000.00$4.56 million$2.85 million
Beta-16.55-3.252.190.73176.15
Average Volume17,513,953937,537192,678180,663,063304
Sales & Book Value
Annual RevenueN/A$69.76 millionN/AN/A$2 million
Price / SalesN/A0.03N/AN/A1.42
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($14.05) per share($6.50) per shareN/AN/AN/A
Price / BookN/A-0.02N/AN/A
Profitability
Net Income$-930,000.00$-31,500,000.00N/AN/A$-380,000.00
EPSN/A($2.96)N/AN/AN/A
Trailing P/E Ratio0.00N/A0.000.000.00
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-39.28%N/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)-298.11%-12.18%N/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current RatioN/A0.43%N/AN/AN/A
Quick RatioN/A0.28%N/AN/AN/A
Ownership Information
Institutional Ownership PercentageN/A7.31%N/AN/A2.55%
Insider Ownership Percentage0.02%12.00%2.08%N/A42.80%
Miscellaneous
Employees159218N/A
Shares Outstanding504.29 million17.87 million13.85 million7.60 billion79,000
Next Earnings DateN/A5/5/2021 (Estimated)N/AN/AN/A
OptionableNot OptionableOptionableOptionableNot OptionableNot Optionable
SourceHeadline
Capstone Therapeutics (OTCMKTS:CAPS) Stock Price Up 5.9%Capstone Therapeutics (OTCMKTS:CAPS) Stock Price Up 5.9%
americanbankingnews.com - April 15 at 12:24 AM
Capstone Therapeutics Announces Operating Results for Fiscal 2020 - Including a Change in Its Deferred Tax Valuation AllowanceCapstone Therapeutics Announces Operating Results for Fiscal 2020 - Including a Change in Its Deferred Tax Valuation Allowance
finance.yahoo.com - March 31 at 6:16 PM
Capstone Therapeutics Announces Results of Special Shareholder Meeting, and a License Transfer/Royalty Agreement and Exit from the Pharmaceutical Development BusinessCapstone Therapeutics Announces Results of Special Shareholder Meeting, and a License Transfer/Royalty Agreement and Exit from the Pharmaceutical Development Business
finance.yahoo.com - February 18 at 5:55 PM
Amhersts restructuring business sold to Boston investment bankAmherst's restructuring business sold to Boston investment bank
crainsdetroit.com - January 13 at 10:11 PM
Capstone Companies, Inc. Receives $750,000 Credit Line from Management MembersCapstone Companies, Inc. Receives $750,000 Credit Line from Management Members
us.acrofan.com - January 5 at 6:36 PM
Capstone Therapeutics Announces Exercise of Secured Debt and Interest Conversion Option by BP Peptides, LLC and Change in ControlCapstone Therapeutics Announces Exercise of Secured Debt and Interest Conversion Option by BP Peptides, LLC and Change in Control
finance.yahoo.com - December 28 at 5:05 PM
ONL Therapeutics Raises $46.9M in Series B FinancingONL Therapeutics Raises $46.9M in Series B Financing
finsmes.com - December 26 at 1:01 AM
CapStone Holdings Invests $25M In TerrAscends Ilera Healthcare DivisionCapStone Holdings Invests $25M In TerrAscend's Ilera Healthcare Division
benzinga.com - December 23 at 6:24 AM
Adial Pharmaceutical, Inc.: Adial Pharmaceuticals Appoints Dr. Jack Reich as Head of RegulatoryAdial Pharmaceutical, Inc.: Adial Pharmaceuticals Appoints Dr. Jack Reich as Head of Regulatory
finanznachrichten.de - December 17 at 10:34 PM
TSX Positive to Begin WeekTSX Positive to Begin Week
baystreet.ca - December 14 at 3:10 PM
Alcresta Therapeutics Appoints Alan Muney, MD To Board Of DirectorsAlcresta Therapeutics Appoints Alan Muney, MD To Board Of Directors
pharmiweb.com - December 7 at 3:39 PM
Capstone Therapeutics Corp (CAPS) - Cash FlowCapstone Therapeutics Corp (CAPS) - Cash Flow
fool.com - November 29 at 8:55 PM
Capstone Therapeutics Corp.Capstone Therapeutics Corp.
barrons.com - November 16 at 6:38 PM
Alcresta Therapeutics RELiZORB® (iMMOBILIZED LIPASE) Cartridge Shows Long-term Effectiveness In Enterally Fed Patients With Cystic FibrosisAlcresta Therapeutics' RELiZORB® (iMMOBILIZED LIPASE) Cartridge Shows Long-term Effectiveness In Enterally Fed Patients With Cystic Fibrosis
prnewswire.com - November 11 at 11:27 AM
Proactive news headlines: Alien Metals Ltd, Ferro-Alloy Resources Ltd, Quadrise Fuels International PLC, Sensyne Health PLCProactive news headlines: Alien Metals Ltd, Ferro-Alloy Resources Ltd, Quadrise Fuels International PLC, Sensyne Health PLC
proactiveinvestors.co.uk - October 28 at 6:55 PM
Pokemon Sword & Shields Galarian Star Tournament is Toughest Challenge in GamePokemon Sword & Shield's Galarian Star Tournament is Toughest Challenge in Game
comicbook.com - October 21 at 1:02 PM
Capstone Therapeutics Corp (CAPS)Capstone Therapeutics Corp (CAPS)
nasdaq.com - October 20 at 7:27 PM
Wearable device startup Encora Therapeutics brings in $1.5M pre-seed roundWearable device startup Encora Therapeutics brings in $1.5M pre-seed round
bizjournals.com - September 30 at 6:43 PM
Allegian, exactEarth at 52-Week Highs on NewsAllegian, exactEarth at 52-Week Highs on News
baystreet.ca - September 10 at 1:07 PM
Leadership Tracks and Capstone ProjectsLeadership Tracks and Capstone Projects
www.med.stanford.edu - July 26 at 7:45 PM
Mobile addiction care service to offer outreach to high-risk populationsMobile addiction care service to offer outreach to high-risk populations
www.umassmed.edu - June 24 at 12:34 PM
Akari Therapeutics: An Investment AssessmentAkari Therapeutics: An Investment Assessment
seekingalpha.com - June 16 at 7:21 AM
Artificial nose shows potential to treat breathing disordersArtificial nose shows potential to treat breathing disorders
medicalxpress.com - June 4 at 10:16 AM
Stanford pivots its Long-Range Vision to contribute to global recoveryStanford pivots its Long-Range Vision to contribute to global recovery
news.stanford.edu - May 22 at 9:57 AM
For American orchestras, survival lessons from the woman who rescued the L.A. PhilFor American orchestras, survival lessons from the woman who rescued the L.A. Phil
www.latimes.com - May 1 at 6:11 PM
DateCompanyBrokerageAction
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.